The FDA gave fast-track status to Astellas' acute myeloid leukemia treatment gilteritinib, an FLT3/AXL tyrosine kinase inhibitor. The drug improved overall survival in patients with FLT3 mutation-positive relapsed/refractory AML in clinical trials.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.